December 21, 2023 General News

Acadia Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024

SAN DIEGO–(BUSINESS WIRE)–Dec. 21, 2023– Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024, at 9:00 a.m. Pacific Time, followed by a question and answer session.

A live webcast of Acadia’s presentation will be accessible on the company’s website, www.acadia.com, under the investors section and an archived recording will be available on the website for approximately one month following the presentation.

About Acadia Pharmaceuticals

Acadia is advancing breakthroughs in neuroscience to elevate life. For 30 years we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only approved therapies for hallucinations and delusions associated with Parkinson’s disease psychosis and for the treatment of Rett syndrome. Our clinical-stage development efforts are focused on treating the negative symptoms of schizophrenia, Prader-Willi syndrome, Alzheimer’s disease psychosis and neuropsychiatric symptoms in central nervous system disorders. For more information, visit us at www.acadia.com and follow us on LinkedIn and Twitter.

Media Contact:
Acadia Pharmaceuticals Inc.
Deb Kazenelson
(818) 395-3043
media@acadia-pharm.com

Investor Contact:
Acadia Pharmaceuticals Inc.
Al Kildani
(858) 261-2872
ir@acadia-pharm.com

Acadia Pharmaceuticals Inc.
Jessica Tieszen
(858) 261-2950
ir@acadia-pharm.com

Source: Acadia Pharmaceuticals Inc.

Media Contact

Investor Contact